Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Citius Pharmaceuticals Inc (CTXR) vs Mizuho Financial Group Inc. Sponosred ADR (Japan) (MFG) Price & Performance

Citius Pharmaceuticals IncTrade
Mizuho Financial Group Inc. Sponosred ADR (Japan)Trade

Price performance (Past 24H)

Key statistics

Citius Pharmaceuticals Inc vs Mizuho Financial Group Inc. Sponosred ADR (Japan) — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while Mizuho Financial Group Inc. Sponosred ADR (Japan) trades at $10.59 (market cap $127.85B). The key difference: Mizuho Financial Group Inc. Sponosred ADR (Japan) is far larger — about 9386.9× Citius Pharmaceuticals Inc's market cap, and Mizuho Financial Group Inc. Sponosred ADR (Japan) pays a 1.72% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Mizuho Financial Group Inc. Sponosred ADR (Japan) for 0 Days on average.

CTXRMFG
Market Cap
$13.62M$127.85B
Volume
132,4383,950,750
Sector
HealthFinancials
52-Week High
$1.82$11.45
52-Week Low
$0.48$6.09
Typical Hold Time
16 Days0 Days
Enterprise Value
$3.79M$35.14T
Dividend Yield
—1.72%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Citius Pharmaceuticals Inc

CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.

The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.

Mizuho Financial Group Inc. Sponosred ADR (Japan)

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

CTXR
2% Buy98% Sell
Avg holding period · 16 Days
MFG
100% Buy0% Sell
Avg holding period · 0 Days

About Citius Pharmaceuticals Inc

Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.

Read more on CTXR →

About Mizuho Financial Group Inc. Sponosred ADR (Japan)

Mizuho Financial Group is a Japanese financial services company offering banking, trust, securities, and asset management services. It serves retail, corporate, and institutional clients globally.

Read more on MFG →